Dr. Liza C. Villaruz
Claim this profileUniversity of Pittsburgh Cancer Institute (UPCI)
About Liza C. Villaruz
Education:
- Obtained MD from the University of Pittsburgh School of Medicine in 2010.
- Completed Residency in Radiation Oncology at the University of Pittsburgh Medical Center in 2015.
- Finished Fellowship in Radiation Oncology at the University of Pittsburgh Cancer Institute in 2016.
Experience:
- Assistant Professor of Radiation Oncology at the University of Pittsburgh School of Medicine.
- Radiation oncologist at the University of Pittsburgh Cancer Institute, with a specialization in breast cancer and gastrointestinal malignancies.
Area of expertise
Lung Cancer
Liza C. Villaruz has run 29 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Liza C. Villaruz has run 20 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of Pittsburgh Cancer Institute (UPCI)
UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Clinical Trials Liza C. Villaruz is currently running
Chemotherapy + Immunotherapy
for Mesothelioma
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid and may kill cancer cells. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with usual treatment may work better than usual treatment alone.
Recruiting
1 award
Phase 2
36 criteria
LY3537982 + Immunotherapy/Chemotherapy
for Non-Small Cell Lung Cancer
This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
Recruiting
1 award
Phase 3
14 criteria
More about Liza C. Villaruz
Clinical Trial Related
7 years of experience running clinical trials · Led 40 trials as a Principal Investigator · 12 Active Clinical Trials
Treatments Liza C. Villaruz has experience with
- Pembrolizumab
- Carboplatin
- Pemetrexed
- Atezolizumab
- Berzosertib
- Irinotecan Hydrochloride
Breakdown of trials Liza C. Villaruz has run
Lung Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
- Atezolizumab + Cobimetinib for Lung Cancer
Non-Small Cell Lung Cancer
Cancer
- Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab
- M6620 + Topotecan for Small Cell Lung Cancer
- Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
Pancreatic Cancer
Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Liza C. Villaruz specialize in?
Liza C. Villaruz focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Liza C. Villaruz currently recruiting for clinical trials?
Yes, Liza C. Villaruz is currently recruiting for 12 clinical trials in Pittsburgh Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Liza C. Villaruz has studied deeply?
Yes, Liza C. Villaruz has studied treatments such as Pembrolizumab, Carboplatin, Pemetrexed.
What is the best way to schedule an appointment with Liza C. Villaruz?
Apply for one of the trials that Liza C. Villaruz is conducting.
What is the office address of Liza C. Villaruz?
The office of Liza C. Villaruz is located at: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania 15232 United States. This is the address for their practice at the University of Pittsburgh Cancer Institute (UPCI).
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.